Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches.

about

Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia.

P2860

Q39010254-F9BB3355-3D76-4F83-BB77-3D7190D81D54

P2860

Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches.

Item

http://www.wikidata.org/entity/Q41479614

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Assessment of the persistence ...... cokinetic modeling approaches.

@en

type

Item

label

Assessment of the persistence ...... cokinetic modeling approaches.

@en

prefLabel

Assessment of the persistence ...... cokinetic modeling approaches.

@en

P1476

Assessment of the persistence ...... cokinetic modeling approaches.

@en

P2093

Alice Ban Ke

http://www.w3.org/2001/XMLSchema#string

David S Small

http://www.w3.org/2001/XMLSchema#string

Matthew Rotelli

http://www.w3.org/2001/XMLSchema#string

Nathan Mantlo

http://www.w3.org/2001/XMLSchema#string

Stephen D Hall

http://www.w3.org/2001/XMLSchema#string

Stuart Friedrich

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal Structures of Cholesteryl Ester Transfer Protein in Complex with Inhibitors

Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib

Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction

Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults

A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State.

Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

The pharmacokinetics and pharmacokinetic/pharmacodynamic relationships of evacetrapib administered as monotherapy or in combination with statins.

Physiologically-based pharmacokinetics in drug development and regulatory science.

P304

757-767

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.472

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25651523

http://www.w3.org/2001/XMLSchema#string

Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches.

about

P2860

P2860

Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698